Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Urology Hematology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Cellulitis

Subtypes of Cellulitis

Orbital cellulitis 2

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cellulitis

16 trials tracked for Cellulitis: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 1511 citations.

16Trials tracked

7Phase 3 & 4

0Recruiting

4With published results

Phase distribution

Phase 4 2 Phase 3 5 Phase 2 4 Other / NA 5

Phase 4 High-dose vs. Standard-dose Cephalexin for Cellulitis Completed · 1,511 cited
Phase 3 Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I) Completed · 302 cited
Phase 3 Oritavancin Versus IV Vancomycin for the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infection Completed · 218 cited
Phase 3 Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed · 215 cited
Phase 4 Evaluation of Daptomycin for the Emergency Department Treatment of Complicated Skin and Skin Structure Infections Completed
Phase 3 Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed

Show 10 more trials

Phase 3 Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Completed
Phase 2 Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis Completed
Phase 2 A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study Completed
Phase 2 Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage Completed
Phase 2 Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) Completed
N/A Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients Completed
N/A RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction Completed
N/A The Personalised Antibiotic Duration for Cellulitis (PAD-C) Study Completed
N/A Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis Completed
N/A Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program Completed

Showing the 16 most-cited and recently-updated of 16 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Cellulitis: what the trials found

Several antibiotic agents have been evaluated for the treatment of cellulitis. Single-dose IV Oritavancin Diphosphate demonstrated clinical efficacy in patients with cellulitis, with a significant number of patients achieving cessation of spread or reduction in lesion size, absence of fever, and no need for rescue antibiotics at early clinical evaluation [4, 5]. Additionally, Dalbavancin was evaluated as an IV treatment; approximately 81-84% of participants showed clinical response within 48-72 hours of initiation, with consistent clinical status observed at the end of treatment [6, 7, 8].

Other established pharmacological interventions for cellulitis include Cephalexin ² and Daptomycin ³.

Recent results — preliminary, needs further review

A recent study reported a 70% recovery rate at 28 days and a 72% patient-reported recovery rate by 28 days in patients with cellulitis, alongside an 8.0 point improvement on the SF-12 physical component score ¹.

For the clinician treating this condition

Single-dose IV Oritavancin Diphosphate is established as an effective option for achieving early clinical evaluation goals including lesion reduction and fever resolution [4, 5].
IV Dalbavancin shows high rates of clinical response (over 80%) within the first 48-72 hours of treatment [6, 7, 8].
Cephalexin and Daptomycin are established pharmacological options for managing cellulitis [2, 3].

AI synthesis of 3 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.